Safe and effective vaccines take a leap forward

11 January 2021

Empowered by a groundswell of support from donors like you, our researchers worked tirelessly in 2020 to fast-track the development of new vaccine technology in response to the COVID-19 pandemic.

While UQ’s COVID-19 vaccine candidate was unable to progress to Phase 2/3 trials, the results of Phase 1 demonstrated the novel ‘molecular clamp’ technology is a viable option for future rapid-response needs.

“What is encouraging is that the core technology approach we used has passed the major clinical test. It is a safe and well-tolerated vaccine, producing the strong virus-neutralising effect that we were hoping to see,” Professor Paul Young, UQ vaccine co-lead, said.

Professor Young said the researchers were blown away by the response of the community who joined the cause.

“The ongoing community support has been one of things that has propelled the team forward this year and kept spirits high,” he said.

“The progress we’ve made, and the speed at which we’ve been able to work, shows what happens when people get behind a scientific project.”

Thank you for bringing this world-changing research to life.

Read the full tribute to our amazing researchers and the generous donor community.